Home Hemodialysis Patents: Who Leads, Where the Gaps Are 2026
- One filer dominates the leader board. The top-ranked assignee holds 80 records against a fifth-place count of 22 and a tenth-place count of 5 — a steep drop-off rather than a gradual one.
- Software classes now rival the hardware class. G16H healthcare informatics appears on 52.9% of the 189 records in scope and G06F data processing on 48.1%, both close behind A61M body-fluid devices at 57.1%.
- Filing has cooled from its 2020 peak. Volume peaked at 14 in 2020; from 2021 (7) to 2024 (4) — the last complete filing year — the documented figure is a 43% decline.
Filing growth compares 2021 (7 records) with 2024 (4) — a three-year span. 2024 is the most recent year we treat as complete: publication lags filing by roughly 18 months, so 2025 onwards are still filling in and any growth rate that ends there would understate the field.
What this landscape covers
This dataset tracks patent families addressing home hemodialysis and remote monitoring — machines simplified for home use, patient training workflows, treatment frequency management, data upload from dialysis devices, adverse event alerting and the supply logistics that keep a home patient in consumables. It spans records published between 2015 and mid-2026, with 189 records in scope.
Because publication trails filing by roughly 18 months, the most recent filing years in this set are undercounts by construction — 2024 is the last year that can be read as a complete picture, and 2025-2026 will keep filling in as later publications land.
Let an AI agent run this analysis on your own technology
Pick a task. Every answer cites the patents behind it.
Filing trend and technology composition
Two views of the same 189 records: how filing activity has moved year over year, and which IPC subclasses the claims actually sit in.
Filing trend, 2017-2026
Filings ran from 12 in 2017 to a peak of 14 in 2020, then declined; 2021 (7) to 2024 (4) is a documented 43% drop over the last three complete years. 2025 and 2026 figures are still incomplete due to publication lag and should not be read as a continuation of the decline.
IPC subclass composition
A61M (body-fluid devices) leads at 57.1% of the 189 records, followed closely by G16H (healthcare informatics) at 52.9% and G06F (data processing) at 48.1%. Because records can carry multiple IPC codes, these shares sum to well over 100% — the density in G16H and G06F relative to A61M signals that the informatics and software layer around the dialysis machine is now claimed almost as heavily as the machine itself.
Shares are the percentage of the 189 records in scope. A patent can carry several IPC classes, so the shares add up to more than 100%.
Go deeper on Home Hemodialysis and Remote Monitoring with Eureka
This page is one run against one query. Ask Eureka your own question about home hemodialysis and remote monitoring and every answer comes back with the patent numbers behind it.
Try EurekaMost-cited records in this set
Therapy prediction and optimization for renal failure blood therapy, especially home hemodialysis
A method of predicting serum phosphorus concentrations in a patient during hemodialysis includes measuring serum phosphorus concentrations of the patient over a hemodialysis treatment session time and an ultrafiltration rate calculated by a difference between pre- and post-dialytic body weight of the patient during an initial hemodialysis treatment session divided by a total treatment time of the treatment session and estimating a phosphorous mobilization clearance and a pre-dialysis distribution volume of phosphorus for the patient.US8845570B2 — filed by Vantive US Healthcare, granted 2014-09-30.
| # | Publication no. | Patent title | Citations |
|---|---|---|---|
| 1 | US20130310726A1 | Home Medical Device Systems and Methods for Therapy Prescription and Tracking, Servicing and Inventory | 216 |
| 2 | US20040111294A1 | System and a method for providing integrated access management for peritoneal dialysis and hemodialysis | 195 |
| 3 | US20190358387A1 | Sensor monitoring system for in-dwelling catheter based treatments | 169 |
| 4 | US20110105979A1 | Patient treatment and monitoring systems and methods | 130 |
| 5 | US10089443B2 | Home medical device systems and methods for therapy prescription and tracking, servicing and inventory | 118 |
| 6 | US20040111293A1 | System and a method for tracking patients undergoing treatment and/or therapy for renal disease | 113 |
| 7 | US20140042092A1 | Therapy prediction and optimization of serum potassium for renal failure blood therapy, especially home hemod… | 110 |
| 8 | US20130211206A1 | Patient Treatment and Monitoring Systems and Methods with Cause Inferencing | 84 |
| 9 | WO2009083011A2 | A method for dialysis fluid regeneration | 78 |
| 10 | US8632485B2 | Patient treatment and monitoring systems and methods | 73 |
Citation counts inside a searched corpus favour older filings that have had more time to accumulate citations — read them as a signal of influence on later filers, not as a measure of current technical importance.
Each row carries its publication number; clicking a row searches Eureka by that number.
Put your own technology through the same analysis
Eureka on the web
When you want the answer in the next five minutes.
The agent works the prompt against patents and technical literature, citing every source.
Run your analysis now →MCP server & REST API
When it has to run inside your own pipeline.
Patent search, landscape analysis and assignee resolution as MCP tools. Drop them into any agent framework, or call REST directly.
Browse MCP servers →What the data means for strategy
Three findings that shape where to file, license or design around in this field.
The leader board drops off sharply
The top-ranked assignee holds 80 of the ranked records; by fifth place that figure is down to 22, and by tenth place to 5. That is a steep gradient rather than a flat field, which means most of the accumulated claim history in home hemodialysis sits with a small number of related entities rather than being spread across many independent filers.
Informatics claims now track the hardware closely
G16H (healthcare informatics) appears on 52.9% of records and G06F (data processing) on 48.1%, both trailing A61M (body-fluid devices, 57.1%) by a relatively narrow margin. Claims on the software and data layer — training workflows, adverse-event alerting, data upload — are nearly as dense as claims on the physical dialysis hardware itself.
Volume has cooled since the 2020 peak
Filings peaked at 14 in 2020 and fell to 4 by 2024, a documented 43% decline across that three-year window. Recent-year momentum by assignee also shows the leading filers at 0 in the latest tracked year, though this should be read alongside the 18-month publication lag rather than as a sign the field is closed.
Eureka can read the same corpus for gaps instead of for coverage: under-claimed branches adjacent to home hemodialysis and remote monitoring, with the prior art for and against each one.
Who holds the claim space
A small set of related assignees anchors the ranked field, with co-assignee pairs suggesting corporate restructuring rather than independent competition.
One franchise dominates by volume
The top-ranked assignee's 80 records dwarf the rest of the field. Strong co-assignee pairing between related entities (one pair co-appears on 134 records) points to a single corporate lineage — likely a spin-out or rebrand — rather than genuinely separate competitors holding the bulk of the claim space.
A long tail below the leader
From fifth place (22 records) to tenth place (5 records), the ranking thins quickly. This is where opportunistic and single-purpose filers — device makers, monitoring-software vendors, and at least one named individual inventor — hold small but potentially blocking positions in narrow sub-claims.
Momentum has paused at the top
The leading assignees each show 0 filings in the latest tracked year. Given the 18-month publication lag, this is consistent with filings still working through the pipeline rather than a confirmed retreat from the space.
| Assignee | Recent year | YoY |
|---|---|---|
| Baxter International Inc. | 0 | — |
| Baxter Healthcare SA | 0 | — |
| Fresenius Medical Care Holdings Inc. | 0 | — |
| Vantive US Healthcare LLC | 0 | — |
| VANTIVE HEALTH GMBH | 0 | — |
| GastroKlenz Inc. | 0 | — |
| Advance Co., Ltd. | 0 | — |
| PROSL FRANK | 0 | — |
Where to take this analysis
The dataset points to specific next steps depending on whether you are clearing a design, scouting licensing targets, or tracking a competitor.
Screen the under-claimed branches
G06N (AI models) and H04L (digital transmission) each sit at 2.1% and 1.6% of records respectively — thin enough that a well-drafted first claim in adverse-event prediction or home-device data transmission protocols may still find open space.
Explore white space in Eureka →Map the co-assignee lineage before licensing
The strongest co-assignee pairs suggest corporate restructuring among the leading filers. Before approaching any of them for a license, confirm current ownership of the specific families you need.
Trace assignee lineage in Eureka →Watch the next 18 months of publications
2025-2026 filing counts will keep rising as publication catches up with filing. Re-check the trend after that window closes before concluding the field has slowed for good.
Set a monitoring alert in Eureka →Common questions on this landscape
One assignee leads the ranked field with 80 records, well ahead of the fifth-ranked filer at 22 and the tenth-ranked filer at 5. Co-assignee data shows this leader sharing a very high number of records (134) with a closely related entity, which points to a single corporate lineage across what may look like two separate names. Anyone assessing competitive concentration in this space should treat those related entities as one bloc rather than as independent competitors.
Filing peaked at 14 records in 2020 and declined to 4 by 2024, a documented 43% drop across that three-year window — this is the last period that can be read as complete. Counts for 2025 and 2026 are still low, but that reflects the roughly 18-month lag between filing and publication rather than confirmed inactivity. A fair read is that the field has cooled from its 2020 peak, with the 2025-2026 picture still forming.
Devices for body fluids (A61M) lead at 57.1% of the 189 records in scope, but healthcare informatics (G16H) at 52.9% and general data processing (G06F) at 48.1% are close behind. That gap is narrow enough to say the informatics and monitoring-software layer is claimed almost as heavily as the physical dialysis hardware. Business/administrative data processing (G06Q) and diagnostic/surgical claims (A61B) trail at 22.2% and 18.5% respectively, with water treatment, AI models and digital transmission each under 3%.
US8845570B2 covers a method for predicting serum phosphorus concentrations during hemodialysis, using measured concentrations and an ultrafiltration rate derived from pre- and post-dialytic body weight change over a treatment session. It blocks approaches that estimate phosphorus mobilization clearance and pre-dialysis distribution volume from that specific measurement pathway to predict phosphorus levels at other points in treatment. Anyone building a phosphorus-prediction or dosing-optimization feature for home hemodialysis should review this claim scope before relying on the same weight-change-to-clearance calculation method.
The thinnest IPC subclasses in this dataset are C02F (water and wastewater treatment) and G06N (AI-based computing models), each at 2.1% of the 189 records, and H04L (digital information transmission) at 1.6%. These low shares suggest claim space is still open around AI-driven adverse-event prediction, dialysate/wastewater treatment integration, and transmission protocols purpose-built for home dialysis devices. Given the concentration at the top of the assignee ranking, these under-claimed branches may also be more approachable for new entrants than the core machine and monitoring claims.
Research Home Hemodialysis and Remote Monitoring in depth with Eureka
Go past this page: query the whole home hemodialysis and remote monitoring corpus yourself, in your own scope.
Every answer comes back with patent numbers you can open.
Disclaimer. This page is generated from Patsnap Eureka data drawn from a limited snapshot of global patent and scientific-literature records, and is provided for general information and reference only.
Patent data carries inherent limitations: recent filings (typically the most recent 18–24 months) are under-counted due to standard publication lag; counts may be reported at either a patent-family or a patent-record basis and are not always directly comparable; classification, applicant-name, and citation data may contain errors, duplicates, or omissions; and the underlying search query defines and constrains the scope shown. As a result, the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing on this page constitutes an exhaustive prior-art, novelty, freedom-to-operate, or validity search, nor does it constitute legal, financial, investment, or professional advice, and it should not be relied upon as such. Any patent, commercial, or strategic decision should be verified independently and reviewed with qualified patent, legal, and domain professionals. Patsnap makes no warranties, express or implied, as to the accuracy, completeness, or fitness for any particular purpose of the information presented.
Machine translation. Assignee and organisation names originally recorded in Chinese, Japanese or Korean have been rendered into English by an AI translation step so that the tables stay readable. These renderings are best-effort and may not match a company’s registered English name; the original name is what the underlying patent record carries, and it is what any Eureka query launched from this page uses.